Deborah Heart and Lung Center recently announced it successfully implanted the AVEIR DR, the world’s first dual-chamber leadless pacemaker system from Abbott, which effectively treats people with abnormal or slow heart rhythms.
The groundbreaking system, approved by the U.S. Food and Drug Administration, provides Browns Mills-based Deborah Heart and Lung Center with a new, minimally invasive option to treat the nearly 80% of people who require pacing in two chambers of the heart (both the right atrium and right ventricle).
Unlike traditional pacemakers, leadless devices are implanted directly into the heart through a minimally invasive procedure and eliminate the need for cardiac leads. As a result, leadless pacemakers reduce people’s exposure to potential lead and pocket-related complications and offer a less restrictive and shorter recovery period post-implantation.
“We’re pleased to offer this newly FDA-approved technology to our patients. This is a first for New Jersey and we are excited to be at the forefront of treatment for arrhythmias. The AVEIR DR allows for leadless atrial pacing, which until now was not possible. It expands the options we have for treating irregular heart rhythms,” Dr. Raffaele Corbisiero, division director, electrophysiology and pacing, Deborah Heart and Lung Center, said. “In fact, it is estimated that millions of people across the U.S. require pacing in both chambers of the heart. We look forward to using AVEIR DR to help improve the lives of our patients.”
Roughly one-tenth the size of a traditional pacemaker, the AVEIR DR dual chamber leadless pacing system is made up of two devices — the AVEIR VR ventricular leadless pacemaker, which paces the right ventricle, and the AVEIR AR atrial leadless pacemaker, which paces the right atrium.
AVEIR leadless pacemakers are also engineered to be retrieved should a person’s therapy needs change, or they need a replacement device in the future.